FDA clears Coherent's glaucoma laser:
This article was originally published in Clinica
Coherent has gained FDA 510(k) clearance to market its Selecta 7000 glaucoma laser system in the US. The device is designed to perform selective laser trabeculoplasty (SLT) for the treatment of open angle glaucoma, which the Santa Clara, California company says is the leading cause of preventable blindness in US citizens over the age of 40. SLT reduces intraocular pressure without causing damage to non-melanin-containing cells and the trabecular meshwork structure, adds Coherent.